Skip navigation

Emerging Trends, Best Practices and Benchmarking for Managing Risks Associated with Complex, High-Touch Therapies

September 12-13, 2019
  • Cambridge, MA

CBI’s 5th Annual Compliance Congress for Specialty Products is the life science industry’s only conference catered to the unique compliance challenges for specialty pharmaceutical companies pre- and post-commercialization. At this fifth annual meeting, take advantage of this highly collaborative event to identify and address the top risk zones for orphan and ultra-orphan drug manufacturers and compare strategies for building and maintaining a compliant culture within your organization.

Meet the 2019 Advisory Board!

Heather Golding
VP, Head of Legal and
Compliance, North America
Sobi Inc

Joseph Philipose
Vice President, U.S. and Enterprise Compliance
Alexion Pharmaceuticals

Sarah Whipple
Vice President, Legal and
Chief Compliance Officer
Akebia Therapeutics

Daryl Kreml
Chief Compliance Officer,
Vice President
Sage Therapeutics

David Ryan
Vice President,
Chief Compliance Officer
Epizyme

Katherine Chaurette
Vice President,
Healthcare Law & Compliance
Blueprint Medicines

Join the Compliance Community for Compelling Discussions On:

  • Recently released guidance from FDA and DOJ
  • Risks associated with Patient Support Services
  • Transforming the internal role of the compliance officer
    from policeman to partner
  • Third party risk management
  • State drug pricing
  • Transparent relationships with patient advocacy groups
    and charitable foundations
  • Nurses educator programs
  • And more!

FIVE YEARS OF POWERFUL PROGRAMMING FOR THE INDUSTRY:

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics

I found the agenda and panel discussions highly informative and relevant.

Associate Director, Compliance, PTC Therapeutics

This is the only conference that focuses on compliance for specialty products. The unique forum provides a great opportunity to share best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

Excellent content and presentations. The presenters
were well informed and facilitated thoughtful conversations with audience members. I will be back!

Associate Director, Compliance Operations, Helsinn Therapeutics

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics

5th Annual Compliance Congress for Specialty Products

Emerging Trends, Best Practices and Benchmarking for Managing Risks Associated with Complex, High-Touch Therapies

CBI’s 5th Annual Compliance Congress for Specialty Products is the life science industry’s only conference catered to the unique compliance challenges for specialty pharmaceutical companies pre- and post-commercialization. At this fifth annual meeting, take advantage of this highly collaborative event to identify and address the top risk zones for orphan and ultra-orphan drug manufacturers and compare strategies for building and maintaining a compliant culture within your organization.

Meet the 2019 Advisory Board!

Heather Golding
VP, Head of Legal and
Compliance, North America
Sobi Inc

Joseph Philipose
Vice President, U.S. and Enterprise Compliance
Alexion Pharmaceuticals

Sarah Whipple
Vice President, Legal and
Chief Compliance Officer
Akebia Therapeutics

Daryl Kreml
Chief Compliance Officer,
Vice President
Sage Therapeutics

David Ryan
Vice President,
Chief Compliance Officer
Epizyme

Katherine Chaurette
Vice President,
Healthcare Law & Compliance
Blueprint Medicines

Join the Compliance Community for Compelling Discussions On:

  • Recently released guidance from FDA and DOJ
  • Risks associated with Patient Support Services
  • Transforming the internal role of the compliance officer
    from policeman to partner
  • Third party risk management
  • State drug pricing
  • Transparent relationships with patient advocacy groups
    and charitable foundations
  • Nurses educator programs
  • And more!

FIVE YEARS OF POWERFUL PROGRAMMING FOR THE INDUSTRY:

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics

I found the agenda and panel discussions highly informative and relevant.

Associate Director, Compliance, PTC Therapeutics

This is the only conference that focuses on compliance for specialty products. The unique forum provides a great opportunity to share best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

Excellent content and presentations. The presenters
were well informed and facilitated thoughtful conversations with audience members. I will be back!

Associate Director, Compliance Operations, Helsinn Therapeutics

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics